What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular disease. Intervention: Influenza vaccination vs. Placebo, no vaccination, or standard-dose vaccination.

What does this research mean for the field?

Influenza vaccination reduces major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in higher-risk secondary-prevention populations, with high-dose formulations providing incremental benefits in adults aged 65 years or older. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To summarize evidence linking influenza infection to acute cardiovascular destabilization, evaluate the cardioprotective efficacy of standard and high-dose vaccines, and delineate implementation strategies across clinical pathways.

July 10, 2026Journal of Clinical MedicineOpen Access

Influenza Vaccination as Cardiovascular Prevention in Adults with Heart Disease

View Full Paper

Ask AI

Bookmark

Key result

Influenza vaccination significantly reduces MACE and mortality in high-risk secondary-prevention cardiovascular populations.

Why the study?

Seasonal influenza triggers acute cardiovascular events, making influenza vaccination a potential low-risk, evidence-supported component of cardiovascular prevention rather than solely protection against respiratory disease.

Does influenza vaccination reduce cardiovascular events and mortality in adults with heart disease?

Key Points

To summarize evidence linking influenza infection to acute cardiovascular destabilization, evaluate the cardioprotective efficacy of standard and high-dose vaccines, and delineate implementation strategies across clinical pathways.
Conducted a targeted narrative review searching PubMed/MEDLINE, ClinicalTrials.gov, and major international cardiology guideline consensus statements from inception through May 2026.
Synthesized findings across randomized controlled trials, pragmatic active-comparator trials (such as DANFLU-2, GALFLU, and FLUNITY-HD), and observational analyses.
Influenza infection was linked to an approximately sixfold increase in myocardial infarction risk within the first week of infection, and 12% of adults hospitalized with influenza developed acute cardiovascular complications.
Randomized trials and meta-analyses confirmed that influenza vaccination significantly reduced major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality, most notably after acute coronary syndrome or myocardial infarction.
High-dose inactivated vaccines provided incremental clinical benefits over standard doses in adults aged 65 years or older for influenza or pneumonia, cardiorespiratory, and heart failure hospitalizations.

Structured PICO

Does influenza vaccination reduce cardiovascular events and mortality in adults with heart disease?

Population

A narrative review summarizing the evidence for influenza vaccination as a cardiovascular prevention strategy in adults with established heart disease and older adults.

Intervention

Influenza vaccination (including standard-dose and high-dose/enhanced formulations)

Comparator

Placebo, no vaccination, or standard-dose influenza vaccination

Outcome

Major adverse cardiovascular events, cardiovascular mortality, all-cause mortality, and hospitalizations (influenza/pneumonia, cardiorespiratory, heart failure)hard clinical

Influenza vaccination is a low-risk, evidence-supported component of cardiovascular prevention that reduces mortality and hospitalizations in patients with established heart disease.

Limitations

Observational evidence is vulnerable to confounding, residual confounding, confounding by indication, and healthy-user bias.
Some randomized trials were underpowered for cardiovascular end points, terminated early, or relied on secondary or exploratory analyses.
Incremental evidence for high-dose vaccination comes mainly from older-adult populations and active-comparator trials, which should not be extrapolated uncritically to younger cohorts.
Observational evidence is vulnerable to confounding, residual confounding, confounding by indication, and healthy-user bias
Magnitude of benefit is context dependent (influenza intensity, vaccine effectiveness, timing, baseline risk)
Some randomized trials were underpowered for cardiovascular end points, terminated early, or relied on secondary analyses
Incremental evidence for high-dose vaccination comes mainly from older-adult populations and active-comparator trials and should not be extrapolated uncritically to younger cohorts

Implication

Supports vaccination in secondary CVD prevention; extends meta-analyses but leaves open confirmation from ongoing pragmatic RCTs.

Abstract

Seasonal influenza is not only a respiratory infection but also a clinically relevant trigger of acute cardiovascular events. In adults with established cardiovascular disease, particularly older adults and patients with recent acute coronary syndrome or heart failure, influenza vaccination should be considered a low-risk, evidence-supported component of cardiovascular prevention rather than solely protection against respiratory disease. The evidence addresses three related but distinct questions: influenza infection as a cardiovascular trigger; influenza vaccination versus placebo or no vaccination; and enhanced or high-dose vaccination versus standard-dose vaccination. Randomized trials and meta-analyses support reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in higher-risk secondary-prevention populations, with particularly persuasive evidence after myocardial infarction. Recent pragmatic active-comparator trials of high-dose inactivated influenza vaccine, including DANFLU-2 and GALFLU, and the individual-level pooled FLUNITY-HD analysis provide incremental evidence in adults aged 65 years or older, strongest for hospitalization for influenza or pneumonia, cardiorespiratory hospitalization, and heart failure hospitalization. The current priority is implementation: screening, offering, documenting, and communicating vaccination across hospitalization, outpatient cardiology, cardiac rehabilitation, heart failure pathways, primary care, pharmacies, and long-term care. Influenza vaccination should complement, not replace, established guideline-directed cardiovascular therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Figures from the paper

Published by Journal of Clinical Medicine · CC BY

Cite This Study

Bonanad et al. (2026) conducted a review in Cardiovascular disease. Influenza vaccination vs. Placebo, no vaccination, or standard-dose vaccination was evaluated. Influenza vaccination reduces major adverse cardiovascular events and mortality in high-risk secondary-prevention populations and should be integrated into routine cardiovascular care.

synapsesocial.com/papers/6a508bde6eeac72a437a03ba https://doi.org/10.3390/jcm15145343

View Full Paper

Ask AI

Bookmark

Implication

Supports vaccination in secondary CVD prevention; extends meta-analyses but leaves open confirmation from ongoing pragmatic RCTs.

Influenza Vaccination as Cardiovascular Prevention in Adults with Heart Disease

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

Influenza Vaccination as Cardiovascular Prevention in Adults with Heart Disease

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

Keep reading

Keep reading